The world might be facing turmoil and uncertainty — states that Novavax Inc. knows all too well — but today, the Gaithersburg biotech has reason to celebrate.
The company has reported positive results for its late-stage clinical trial of seasonal flu vaccine NanoFlu, marking its first successful phase 3 study after two devastating failures. These latest results now open an otherwise impenetrable door with a product candidate viewed as Novavax's last best chance for success — and its first-ever commercial product in more than 30 years of operation.